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INTRODUCTION
Tuberculosis (TB) is the leading cause of  morbidity
and mortality among people living with Human
Immunodefi­ciency Virus (HIV), particularly in
developing countries1. The disease is a major public
health problem in Nigeria, with the country ranking
5th among the 22 high TB burden countries which
collectively bear 80% of the global burden of TB 2.
The number of TB cases notified in the country
increased from 31,264 in 2002 to 90,307 in 2008 and
20 – 30% of these patients had HIV co-infection 2.
The disease has been shown to progress more rapidly
and management poses more challenges in those co-
infected with HIV 3. Thus, there is the need for studies
evaluating interactions between the two diseases to
guide development of  effective treatment policies.
Effective chemotherapy is the mainstay of treatment
of tuberculosis and this is largely based on patients’
willingness to comply with prescribed regimen.
Adverse Drug Events (ADEs) and Adverse Drug
Reactions (ADRs) are significant factors in the
compliance of  patients to medications. These reactions
are more common when drugs are taken frequently,
in combination, and over prolonged periods. Despite
the high level of under-reporting of actual and
suspected ADRs 4, it has been shown that adverse drug
reactions can be significant factors in the treatment of
chronic conditions like tuberculosis 5,6. Studies
conducted in developing countries have shown that
HIV status is a risk factor for the development of
anti-TB drug reactions 7.
Many published reports on anti-TB ADEs are from
retrospective studies or are components of studies
whose primary objectives are not the detection of
ADEs. These studies are likely to have reported lower
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Background:  The combination and use of multiple drugs in the treatment of
tuberculosis (TB) predispose to adverse drug events and reactions. This study
evaluated the incidence, frequency, and severity of  adverse events to first line
anti-tuberculosis (anti-TB) drugs in patients with TB and co-infections with
Human Immunodeficiency Virus (HIV).
Objectives: The objective of  this study was to determine the effects of  HIV
status on the risk of  developing adverse events to first line anti-TB therapy.
Method:  The study was carried out between 2006 and 2007 when TB therapy
was administered without concomitant anti-retroviral therapy. Patients with
TB presenting at the chest clinic of  a tertiary hospital were sequentially
enrolled. Those with TB alone were allocated to the first group while those
with TB-HIV infection were allocated to a second group. A checklist of adverse
events to the drugs was used to screen for adverse drug events and reactions
during the period of  anti-TB therapy. Adverse drug events were graded as
serious and others (mild-moderate).
Results: One hundred and three patients completed the study. Thirty one (30.1%)
of the patients had TB-HIV co-infection. Majority (70.4%) of the events were
detected during the first week of  therapy, 92% of  these events were mild-
moderate. Eight (25.5%) of those with TB-HIV co-infection had serious adverse
events. All the serious events occurred in the TB-HIV group. Independent
factors for occurrence of ADEs include HIV status, increasing age, and female
gender.
Conclusions: The rate of adverse drug events among patients on first line anti-
tuberculosis treatment was higher in HIV co-infected patients.
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incidences of ADEs; it has been recommended that
prospective observational study designs ought to be
used in evaluating adverse drugs events and reactions
8. In addition, studies evaluating the effects of HIV
status on ADEs to anti-TB treatment are few, especially
in sub-Saharan Africa. This study evaluated the effects
of HIV status on ADEs to first line anti-TB treatment
using a prospective observational design.
METHODS
Design and treatment protocol: The study was carried out
between January 2006 and June 2007, at the chest clinic
of the medical out patients’ department of the
University College Hospital, a tertiary healthcare center
located in Ibadan, Nigeria. It was a prospective
observational study of  patients aged between 18 and
65 years. The study took place when TB-HIV treatment
allowed for treatment of TB alone before
commencement of  anti-retroviral therapy, thus it was
possible to evaluate anti-TB therapy without
concomitant anti retroviral therapy in patients co-
infected with HIV. Consecutive patients who presented
with clinical, radiological, histological, and/or
microbiological features of pulmonary and/or extra-
pulmonary tuberculosis and gave written/verbal
informed consent agreeing to adhere to the study
protocol were enrolled. HIV diagnosis and voluntary
counseling in those with HIV co-infection was done
at the HIV-AIDS clinic of  the same hospital. Patients
on anti-retroviral drugs, other drugs with potential
interactions with the TB regimen, women who were
pregnant or unwilling to avoid pregnancy during the
study period, and those unable to adhere to study
protocol were excluded from the study.
Once enrollment criteria were fulfilled, the patients were
allocated to two groups. Patients who had TB mono-
infection were allocated to group 1 while those who
had TB and HIV co-infections were allocated to group
2. The patients received first line TB therapy in
accordance to the National TB and Leprosy treatment
guidelines (appendix Ai and Aii)9. Patient demographic
information, findings of  clinical examination, positive
and negative responses were entered into individual
case record forms. This process was carried out before
the commencement of treatment and during all clinic
visits. Laboratory evaluations were not part of  the
protocol for the study.
Search for Adverse Drug Events: All enrolled patients had
detailed clinical examination (history and physical) of
all the systems followed by an interview guided by a
checklist of reported Adverse Drug Events to first
line anti-TB medications. The checklist was compiled
from reported literature on anti-TB drugs side effects
and adverse drug reactions (appendix B). The checklist
was used to screen for adverse events at every clinic
visit during the duration of treatment (eight months).
In this report, all detected reactions and side effects
have been categorized under the term adverse drug
events. This is largely because we did not conduct
causality testing in this study.
Grading of adverse drug eventss: Identified adverse drug
events (ADEs) were graded as follows; Serious: for
adverse drug events causing inability to carry out usual
activities. These reactions were usually more prolonged
and required significant modification or discontinuation
of  anti-TB medications.  Others; for all other events
that do not fall into the above category. Orange – red
discoloration of urine attributable to rifampicin was
not considered an adverse drug event in this study and
patients were informed and reassured of  this
occurrence. This is a modification of conventional
classification of adverse drug reactions into mild,
moderate, and serious(which includes severe grades)10.
Cure: A patient who met the inclusion criteria for this
study and whose symptoms, signs and laboratory
findings were significantly improved in the last month
of treatment and on at least one previous study time
point (and signed as cured by managing chest
physician). Patients who were smear-positive at
diagnosis, who completed eight months of treatment
and who are smear negative at the end of seven months
of treatment were signed as cured 9.
Data analysis: Data analysis was done using STATA
(version 12, USA). Continuous variables were
expressed as means and standard deviation; categorical
variables were expressed as proportions. Comparison
of categorical variables was done using chi-square and
means using the student “t” test. Where the assumption
of  normality was not satisfied, Mann-Whitney’s test
was used to compare the two groups. A p value of
<0.05 was taken as significant. Univariate analysis was
done for all outcome variables to determine estimates
of  incidence rate ratios. Multivariate analysis was done
by Poisson regression model to determine factor
associations. Manuscript writing was facilitated by use
of EndNotes Reference Manager, version 7.0,
Ethical approval: Approval was obtained from the
University of Ibadan/University College Hospital
Institutional Review Committee before commence-
ment of  the study.
RESULTS
One hundred and seventeen of 326 (35.9%) patients
who were diagnosed and scheduled for TB treatment
at the chest clinic, between January 2006 and February
2007, were enrolled into the study.
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Of the 117 eligible patients, 103 (88%) patients
completed the study and constituted the patients
evaluated for adverse drug reactions. Sixty three
(61.28%) of the patients were male while 40 (38.8%)
were females. The duration of  illness was similar in
both groups. Seventy-two (69.9%) of  these patients
had TB mono-infection while 31 (30.1%) had TB-
HIV co-infection (group 2). Extra-pulmonary
tuberculosis was more common in those in group 2
compared to group 1.  Table 1 shows the distribution
of baseline characteristics of the subjects based on
HIV status.
Peripheral neuropathy occurred relatively later (1-2
months of commencing therapy) and lasted for more
than 4 months. Burning and tingling sensation of  the
extremities were the commonest manifestations of
neuropathy. Cutaneous reactions were second to
neuropathy in terms of  frequency. They were reported
by both groups of patients but were more extensive
in patients who had TB-HIV co-infection compared
with those patients who had TB alone. Generalized
skin rash occurred in 7 of the 9 cases of skin rash
reported among group2 patients as against 3 of the
10 cases reported among those who had TB alone.
Study Variable HIV Positive














24 (33.3%) χ2 =  3.05
(0.081)
Weight (median) 51 kg 55 kg Kruskal-Wallis = 2.02
(0.155)
Duration of TB illness
(median)








56 (77.8%) χ2 =  12.59
(<0.0001)
Table 1: Distribution of  baseline characteristics of  the study subjects based on HIV status.
Adverse drug events were reported in both groups
of  patients. In absolute patient numbers, 32 (44.4%)
patients in group1 reported at least one adverse drug
event while 23 (74.2%) patients in group 2 reported
an adverse drug event (ñ-value = 0.01). Cumulatively,
124 adverse drug events were reported; (63 in group1
patients and 62 in group 2 patients). Analysis of these
adverse events (ADEs) showed that the pattern of
systemic affectation of ADEs was similar in both
groups. The majority (70.4%) of  the adverse drug
events was detected during the first week; 93.5% of
these ADEs were mild-moderate and resolved within
3 to 14 days of  commencement of  therapy.
These were fine pruritic papular rashes affecting
different regions of  the body, especially the trunk and
extremities. Table 2 shows the list of  all the ADEs
reported during the study.
Serious ADEs occurred in 8/31 (25.8%) of the
subjects that had TB-HIV co-infection; none occurred
in the TB alone group. Four patients developed florid
generalized skin rash (between the second week to 3rd
month of therapy), four other patients developed
persistent vomiting (2nd week of therapy), severe
diarrhea (3rd week of therapy), jaundice (1st week of
therapy), and anemia (2nd week of  therapy) respectively.
*Kruskal-Wallis test implemented to compare medians because of  heterogeneity of  variances or non-normal distribution of  the two
comparison groups
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Neuropathy 12 12 24
Skin rash 10 9 19
Body weakness 9 6 15
Headache 9 9 18
Pruritus 8 9 17
Vomiting 5 2 7
Insomnia 3 2 5
Anorexia 2 2 4
Arthragia 1 3 4
Mood change 1 0 1
Diarrhea 1 3 4
Dizziness 1 0 1
Stomatitis 1 0 1
Delayed menstruation 0 1 1
Anemia 0 2 2
Jaundice 0 1 1
Total 63 61 124
Table 2: Detected adverse drug reactions during the study period.






HIV status (positive versus negative) 2.87 (1.89 - 4.31) 1.67 (1.04 - 2.68)
Age (26 - 39 years versus 15 - 25 years) 0.82 (0.48 - 1.40) 1.12 (0.64 - 1.97)
Age (40 - 75 years versus 15 - 25 years) 4.88 (2.97 - 8.14) 6.40 (3.57 - 11.49)
Gender (female versus male) 1.66 (1.10 - 2.47) 2.10 (1.36 - 3.25)
Weight (35 - 49 kg versus 50 - 59 kg) 0.522 (0.33 - 0.83) 0.64 (0.40 - 1.02)
Weight (35 - 49 kg versus 60 - 89 kg) 0.62 (0.35 - 1.07) 0.37 (0.20 - 0.71)
Duration of TB illness in months (0 - 4
versus 5 - 14)
1.14 (0.77 - 1.70) 0.82 (0.54 - 1.24)
Extra-pulmonary TB (yes versus no) 1.93 (1.28 - 2.88) 1.38 (0.84 - 2.27)
Table 3: Crude and adjusted incidence rate ratio estimates of  the effects of  HIV status and other characteristics
on adverse drug reactions from tuberculosis medications
*The regression model mutually adjusted all the study variables by included terms as for each subject characteristic as described
above.
These patients had their medications discontinued and
were admitted to the wards for medical care. No death
was recorded during the study.
Table 3 summarizes the relationship between the risks
for ADEs and characteristic features of the patients,
using multivariate analyses. HIV positive status increased
the risk of developing an ADE to TB medications by
about 1.7 fold.  Increase in age and female gender
also increased the risk of developing an ADE.  Higher
weight appeared to decrease the risk of developing
an ADE. 
The treatment outcome was different between the two
groups; almost all (90.3%) the patients with TB alone
met the definition for cure at the end of the study as
against 61.3% of those with TB-HIV (p-value
<0.0001).
DISCUSSION
The management of tuberculosis has continued to
evolve, largely on account of  drug resistance and HIV-
AIDS co-infection. There is increased need for accurate
TB diagnosis and prompt effective treatment of
infected patients. Effective chemotherapy is dependent
on the willingness and ability of patients to adhere to
chemotherapy for the required six to eight months.
This long duration of therapy and the multiple drugs
involved are predisposing factors to adverse drug
events and reactions11. The directed search for adverse
drug events carried out in the study we are reporting
resulted in relatively higher rates than commonly
reported by some studies 6.
Serious adverse drug events pose a challenge in the
management of TB especially in HIV co-infected
subjects. The rate of  serious adverse drug events
recorded in this study was unexpected, however, HIV
co-infection is known to worsen the progression of
tuberculosis and to increase the incidence and severity
of adverse drug reactions12. During the period that
this study was carried out, awareness of availability of
free diagnosis, counseling and treatment of  HIV-AIDS
was low. These in part, culminated into many of  the
patients presenting rather late at late stages of the
disease. Late presentation  is a recognized risk factor
for adverse  reactions to antimicrobial agents including
anti-TB drugs13. In addition, the HIV state is also
known to be associated with high risk of hypersensi-
tivity reactions, up to a hundred times more common
in some reports 14,15. In a study conducted at Canada
in 2003, Yee and colleagues reported that HIV positive
status was associated with occurrence of major side-
effects to first line anti-TB drugs (adjusted hazards ratio
of 3.8)16.
Another factor that may account for the rate of serious
adverse drug events recorded in this study is the
attribution of these findings to drug events on account
of the study design which had the objective of
detecting adverse drug events. There is a huge
proportion of adverse drug events that go unnoticed,
undetected, and unreported in general medical practice
10. This may not be unconnected to general poor
knowledge about them, the difficulty in differentiating
between disease process and drug reactions, and
general disinterest by physicians in searching for adverse
drug reactions and events. Increasing age was found
to be an independent risk factor for development of
ADEs in this study. While chronological age may not
be an independent risk factor for the development of
adverse drug reactions, it has been reported that age-
dependent factors such as poly-pharmacy, multiple
diseases and changes in pharmacokinetics and
pharmacodynamics seem to be responsible for the
risk of developing more adverse drug reactions 17,18.
These factors may account for the same association
between age and ADEs reported by other studies 19-
22.
Other independent factors found to be associated with
ADEs in this study include female gender and extra-
pulmonary TB. The association between female gender
and the risk of adverse drug reactions is not recent
and has been previously reported by many workers20.
Extra-pulmonary TB is not an uncommon finding in
advanced HIV disease, which in this study was
correlated with higher incidence of adverse drug events
and reactions.
Skin rash was the second most common adverse events
in this study although thiacetazone was not used in the
regimen. This is in keeping with previous reports that
the HIV state is associated with high incidence of drug
allergies. Skin rash is also a reported adverse drug
reaction to all the anti-TB medications used in this
study; however, severe skin rash is commoner with
thiacetazone therapy on account of which the use of
the drug is commonly avoided12,23,24. The overall
incidence of  severe skin rash in our study was low.
It is well recognized that most of the anti-TB drugs
are hepatotoxic, however, only a single case of clinical
jaundice was recorded in our study. Studies have
reported similar low rates of clinical jaundice but with
relatively higher rates of asymptomatic elevation of
liver enzymes 25. A better evaluation of hepatotoxicity
would include the assessment of Liver function tests,
which was not done in our study. This was a major
limitation of  our study. Another limitation was not
conducting a causality assessment for the specific drugs
that may have led to the detected ADEs and confirmed
them as specific adverse drug reactions. Our study was
also limited by small sample size, especially in the arm
with TB-HIV co-infection.
The occurrence of majority of the ADEs (48.2%)
during the first week of therapy is consistent with
previous studies which reported that most ADEs occur
within the first few days to weeks of starting therapy
and generally clear within a few days11. This is the period
when patients need closer monitoring as therapy-related
ADEs may lead to poor compliance and to
discomfort. The directed search for ADEs in our study
led to detection of  cases that normally may have gone
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unreported because in many instances, patients do not
complain about them and they resolve within days of
commencing treatment. However, some adverse drug
events e.g. peripheral neuropathies occurred after one
or more months of starting therapy and lasted much
longer. It is advisable that the directed search for
adverse drug reactions should be diligently done
throughout the period of  anti-TB therapy.
In an almost similar design to this study, Chhetri et al
evaluated ADRs caused by first line anti-tuberculous
drugs on directly observed (DOTs) therapy. Their study
showed an ADR prevalence of 54.7%. Almost three-
quarters (70.67%) of the ADRs in that series were
categorized as ‘possibly’ due to the  administered drugs
and 93.33% were classified as ‘mild. They concluded
that occurrence of ADRs from anti-tuberculous drugs
was high in the population of  Western Nepal 26.
CONCLUSIONS
The study was limited by lack of laboratory data for
liver function test, not conducting causality testing, and
a small sample size in the arm with HIV-co-infection,
however, our findings suggest that the rate of  adverse
drug events among patients on first line anti
tuberculosis treatment may be higher in those with HIV
co-infection. Factors found to be associated with
occurrence of ADEs were HIV positive status, older
age, female gender, and extra-pulmonary TB. Routine
monitoring for identification and treatment of ADEs
is essential especially during the first weeks of therapy
and in the follow-up evaluation of patients on treatment
for TB, especially in those co-infected with HIV. Where
anti-TB drugs and other medications are to be
combined e.g. in patients with HIV co-infection,
monitoring of ADEs especially during the first weeks
of commencement of anti-TB regimen becomes
more pertinent. Using a checklist to search for ADEs
may improve the chances of detecting more of them.
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Intensive phase: daily supervised for two months. Combined
tablet of RHZE (150mg+75mg+400mg+275mg) i.e. 4FDCs. 5 4 3 2
Continuation phase: daily for 6 months (monthly collection).
Combined tablet of EH (400mg+150mg) OR
Continuation phase: daily supervised for 4 months. Combined









(i) Treatment regimens when fixed dose combinations (FDCs) were used
Regimen: 2RHZE/6EH or 4RH
Patients less than 30kg were given loose tablets.
Pre-treatment weight and no of tablets
Intensive phase: daily supervised for 2 months.
Ethambutol 400mg (E)















Continuation phase: daily for 6 months
(monthly collection)
Ethambutol 400mg (E) + Isoniazid 150mg combined
tablet.
2 2 1
(ii) Treatment when loose tablets were used
Regimen: 2RHZE/6EH
Key;
Rifampicin (R) Isoniazid (H) Ethambutol (E)
Pyrazinamide (Z)
FDC; fixed dose combination
Appendix: Additional data






























































































































































































































                                                   Annals of Ibadan Postgraduate Medicine. Vol. 14 No. 1 June, 2016               29
